Study of Cytoflavin for ischemic stroke without clot treatment
Part of Brain & nervous system, Heart & circulation clinical trials.
This study is testing a medicine called Cytoflavin for people who have had a recent ischemic stroke but are not receiving clot-busting treatment. It aims to see if Cytoflavin helps improve recovery compared to other treatments or no treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have had an ischemic stroke (a stroke caused by a blood clot) within the last 36 hours
- You are not getting clot-dissolving medicine or a clot-removal procedure
- You have weakness in your arm or leg because of the stroke
- You were able to take care of yourself before the stroke (no major disability)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of CYTOFLAVIN (given as an IV and later as a pill) to help people with long-term symptoms after spending time in the ICU. It aims to improve muscle weakness, breathing, swallowing, and energy levels during later stages of rehabilitation.
This study looks at people who have had an ischemic stroke (a type caused by a blocked blood vessel). It is collecting information over time to better understand care needs and follow-up after stroke.
This study tests whether adding the antibiotic levofloxacin to standard emergency clot-removal (endovascular thrombectomy) is safer and more effective for people with an acute ischemic stroke. It may help by reducing complications after the procedure, but it’s being studied to confirm benefits and risks.
This trial tests if a clot-dissolving medicine can help people who had a mild ischemic stroke and also had a prior stroke in the last 3 months. It aims to see if the treatment is safe and effective for this specific group.
This trial tests whether the antibiotic levofloxacin can be given soon after an acute ischemic stroke to improve outcomes and monitor side effects. It’s for people with a moderate stroke severity who are not having certain emergency treatments or infections.
This trial tests whether adding the antibiotic levofloxacin to standard IV clot-busting treatment is safe and improves outcomes after an acute ischemic stroke. It may help by reducing complications related to infection or inflammation, but you must meet specific heart, liver, kidney, and medication-safety rules.
Hear when a new Stroke, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.